Company news
Recce Pharmaceuticals Ltd. (ASX:RCE) news
Recce Pharmaceuticals Ltd. news releases on 6ix. Latest, Feb 20, 2023: Recce Selects CMAX for Phase I/II UTI Clinical Trial
Press releases — page 3
Recce Selects CMAX for Phase I/II UTI Clinical Trial
February 19, 2023
A$6.21m Received from R&D Rebate Payments
January 24, 2023
JP Morgan Healthcare Conference
January 10, 2023
Australian Patent to be Granted for RECCE Anti-Infectives
January 9, 2023
Anti-Infective Research Unit est. at Murdoch Childrens
December 15, 2022
Approval to Start Phase I/II Diabetic Foot Ulcer Study
December 8, 2022
Anti-Infective Portfolio Update and Webinar details
October 18, 2022
Pause in trading
October 17, 2022
Expansion and Acceleration of Clinical Programs
September 27, 2022
Appendix 4E
August 31, 2022
Phase I Clinical Trial of R327 I.V. - 6000mg Complete
August 21, 2022
Corporate Presentation - Aussie Equities Day 2022
July 28, 2022
Phase I Positive Safety Data - 4000mg Complete
June 21, 2022
Phase I Clinical Trial R327 Advances to 4000mg
May 20, 2022
Corporate Presentation - Biotech Investor Lunch
May 16, 2022
Phase I Clinical Trial R327 Advances to High Dose Cohort
April 12, 2022
Anti-Viral Patent Granted in Hong Kong
April 11, 2022
Positive safety data from 4th Cohort -Phase I Clinical Trial
March 29, 2022
$3.08m R&D Rebate Received
March 28, 2022
Safety Committee Clears PhI R327 Dose Increase
March 6, 2022
S&P DJI Announces March 2022 Quarterly Rebalance
March 4, 2022
Positive Safety Continues in 3rd Cohort PhI Clinical Trial
February 20, 2022
Positive Safety Data from Third Cohort of PI Clinical Trial
February 7, 2022
Positive Safety Data from Second Cohort of PI Clinical Trial
January 18, 2022
Positive Safety Data from Phase 1 Clinical Trial
January 6, 2022
Patients to be Dosed in Ph 1 IV Clinical Trial of R327
December 14, 2021
Update on Phase I/II Clinical Trial for Burn Wound Infection
December 6, 2021
Appendix 4C and Activity Report
October 29, 2021
Ethics Approval to Start Phase 1 Intravenous Clinical Trial
October 24, 2021
Reinstatement to Official Quotation
October 12, 2021
Suspension from Official Quotation
October 11, 2021
Trading halt
October 8, 2021
R327 Phase I Clinical Trial Registered on ANZCTR
September 30, 2021
Recce Receives Further Innovation Connections Grant
August 11, 2021
Anti-Viral Patent Granted in USA for RECCE Anti-Infectives
July 22, 2021
Anti-Viral Patent Granted in China
July 20, 2021
Outstanding Efficacy Against Flesh-Eating Bacteria
July 19, 2021
Multiple Patients Dosed in Topical Phase I/II Clinical Trial
July 11, 2021
Recce Clinical Pipeline Update
June 7, 2021
R327 Demonstrates World First Multiple Mechanisms of Action
May 27, 2021
R327 to Stage 2 of SARS-CoV-2 Antiviral Screening at CSIRO
May 19, 2021
Positive Data on RECCE 327 Against All Six ESKAPE Pathogens
May 3, 2021
RECCE 327 Registered for Topical Burns Study in Humans
April 15, 2021
Positive Sinusitis Patient Update - Special Access Scheme
April 7, 2021
Positive Sinusitis Data Against Infection
March 31, 2021
Anti-Viral Patent Granted in EU for RECCE Anti-Infectives
March 30, 2021
S&P DJI Announces March 2021 Quarterly Rebalance
March 12, 2021
Recce Pharmaceuticals Dual Lists on Frankfurt Stock Exchange
March 7, 2021
Appendix 4D and Half Yearly Report
February 25, 2021
Recce Applies for Dual Listing on Frankfurt Stock Exchange
February 23, 2021